

# **ERSTE STOCK BIOTEC**

**Jointly owned fund pursuant to the InvFG**

Semi-Annual Report 2021

## Contents

General Information about the Investment Firm .....	3
Asset Allocation .....	4
Statement of Assets and Liabilities as of 14 September 2021.....	5

## General Information about the Investment Firm

<b>The company</b>	Erste Asset Management GmbH Am Belvedere 1, A-1100 Vienna Telephone: +43 05 0100-19777, fax: +43 05 0100-919777
<b>Registered capital</b>	EUR 2.50 million
<b>Shareholders</b>	Erste Group Bank AG (64.67%) Erste Bank der österreichischen Sparkassen AG (22.17%) Steiermärkische Bank und Sparkassen Aktiengesellschaft (3.30%) Tiroler Sparkasse Bankaktiengesellschaft Innsbruck (1.74%) DekaBank Deutsche Girozentrale, Frankfurt (1.65%) „Die Kärntner“ Trust-Vermögensverwaltungsgesellschaft m. b. H. & Co KG (1.65%) Salzburger Sparkasse Bank Aktiengesellschaft (1.65%) Sieben Tiroler Sparkassen Beteiligungsgesellschaft m. b. H. (1.65%) NÖ-Sparkassen Beteiligungsgesellschaft m. b. H. (0.76%) VIENNA INSURANCE GROUP AG Wiener Versicherung Gruppe (0.76%)
<b>Supervisory Board</b>	Rudolf SAGMEISTER (Chairman) Thomas SCHAUFLER (Deputy Chairman) Harald GASSER Gerhard GRABNER Harald Frank GRUBER Oswald HUBER Radovan JELASITY Robert LASSHOFER Franz PRUCKNER Rupert RIEDER Gabriele SEMMELROCK-WERZER Reinhard WALT Gerald WEBER Appointed by the Works Council: Martin CECH Regina HABERHAUER Heinrich Hubert REINER Peter RIEDERER Nicole WEINHENGST Manfred ZOUREK
<b>Managing directors</b>	Heinz BEDNAR Winfried BUCHBAUER Peter KARL Thomas KRAUS
<b>Prokuristen (proxies)</b>	Karl FREUDENSCHUSS Manfred LENTNER Günther MANDL Gerold PERMOSER Magdalena REISCHL Oliver RÖDER
<b>State commissioners</b>	Walter MEGNER Christoph SEEL
<b>Auditor</b>	Ernst & Young Wirtschaftsprüfungsgesellschaft m.b.H.
<b>Depository bank</b>	Erste Group Bank AG

## Dear Unit-holder,

We are pleased to present you the following semi-annual report for the ERSTE STOCK BIOTEC jointly owned fund pursuant to the InvFG for the period from 15 March 2021 to 14 September 2021.

## Asset Allocation

	As of 14.09.2021 EUR millions	%
Equities		
USD	245.1	97.83
Transferable securities	245.1	97.83
Bank balances	5.5	2.20
Dividend entitlements	0.1	0.05
Other deferred items	-0.2	-0.08
Fund assets	250.6	100.00

# Statement of Assets and Liabilities as of 14 September 2021

(including changes in securities assets from 15 March 2021 to 14 September 2021)

Security designation	ISIN number	Purch./ additions	Sales/ disposals	Holding Units/nominal (nom. in 1,000, rounded)	Price	Value in EUR	% share of fund assets
<b>Publicly traded securities</b>							
<b>Equities denominated in USD</b>							
<b>Issue country USA</b>							
ALLOGENE THERAP. DL-.001	US0197701065	0	0	40,800	24.860	858,002.79	0.34
ALLOVIR INC. DL-.0001	US0198181036	0	0	16,400	23.420	324,906.31	0.13
ALX ONCOLOGY HLD. DL-.001	US00166B1052	0	0	9,200	78.060	607,496.51	0.24
ARCTURUS THER.HLD.DL-.001	US03969T1097	0	0	6,200	52.430	274,978.64	0.11
ARCUTIS BIOTHER. DL-.0001	US03969K1088	0	0	11,100	21.250	199,530.52	0.08
ARVINAS INC. DL-.001	US04335A1051	12,500	0	22,700	96.000	1,843,420.89	0.74
BEAM THERAPEUTICS DL-.01	US07373V1052	8,500	0	15,000	99.880	1,267,351.86	0.51
FORMA THERAPEUT. DL-.001	US34633R1041	0	0	10,400	23.970	210,876.79	0.08
KARUNA THERAPEUT.DL-.0001	US48576A1007	7,070	0	7,070	115.310	689,626.27	0.28
KEROS THERAPEUTICS -.0001	US4923271013	0	0	5,700	31.740	153,041.49	0.06
NKARTA INC. DL -.0001	US65487U1088	0	0	7,200	27.240	165,907.88	0.07
RELAY THERAP. DL-.001	US75943R1023	0	0	23,100	35.410	691,935.03	0.28
SPRINGWOR.TH.INC.DL-.0001	US85205L1070	0	0	12,300	70.830	736,969.93	0.29
TRANSLATE BIO INC DL-.001	US89374L1044	0	0	20,000	37.360	632,068.69	0.25
TURNING PT. THER.DL-.0001	US90041T1088	0	0	18,700	77.330	1,223,255.09	0.49
VIR BIOTECHN.INC.DL-.0001	US92764N1028	0	0	33,300	50.170	1,413,239.44	0.56
Y-MABS THERAP. DL-.0001	US9842411095	0	0	10,000	33.230	281,098.00	0.11
ZENTALIS PHARMAC. DL-.001	US98943L1070	0	0	9,800	72.040	597,210.17	0.24
Total issue country USA						<u>12,170,916.30</u>	<u>4.86</u>
Total equities denominated in USD translated at a rate of 1.18215						<u>12,170,916.30</u>	<u>4.86</u>
Total publicly traded securities						<u>12,170,916.30</u>	<u>4.86</u>

## Securities admitted to organised markets

### Equities denominated in USD

#### Issue country Belgium

GALAPAGOS N.V. ADR 1	US36315X1019	0	0	1,700	56.810	81,696.06	0.03
Total issue country Belgium						<u>81,696.06</u>	<u>0.03</u>

#### Issue country Cayman Islands

BEIGENE LTD SP.ADR	US07725L1026	0	0	12,500	368.890	3,900,625.98	1.56
ZAI LAB LTD ADR/1	US98887Q1040	0	2,900	10,900	134.590	1,240,985.49	0.50
Total issue country Cayman Islands						<u>5,141,611.47</u>	<u>2.05</u>

## ERSTE STOCK BIOTEC

Security designation	ISIN number	Purch./ additions Units/nominal (nom. in 1,000, rounded)	Sales/ disposals	Holding	Price	Value in EUR	% share of fund assets
<b>Issue country Denmark</b>							
ASCENDIS PH.SP.ADR 1 DK 1	US04351P1012	0	0	14,000	153.540	1,818,347.93	0.73
GENMAB AS SP.ADR/1/10DK 1	US3723032062	0	0	12,000	43.810	444,715.14	0.18
Total issue country Denmark						<u>2,263,063.07</u>	<u>0.90</u>
<b>Issue country Great Britain</b>							
ADAPTH.TH.SP.ADR6 LS-.001	US00653A1079	90,000	0	90,000	5.310	404,263.42	0.16
AMARIN CORP.ADR LS-50	US0231112063	0	0	198,000	5.170	865,930.72	0.35
ASTRAZENECA DL-.25 SP.ADR	US0463531089	81,148	44,800	166,348	55.960	7,874,494.84	3.14
AUTOLUS THERAP. SP.ADR/1	US05280R1005	60,000	0	120,000	6.540	663,875.14	0.26
ROYALTY PHARMA OA DL-0001	GB00BMVP7Y09	0	0	97,000	39.670	3,255,077.61	1.30
Total issue country Great Britain						<u>13,063,641.73</u>	<u>5.21</u>
<b>Issue country Ireland</b>							
HORIZON THERAP.PLC DL-.01	IE00BQPQZ61	0	0	73,600	106.170	6,610,085.01	2.64
Total issue country Ireland						<u>6,610,085.01</u>	<u>2.64</u>
<b>Issue country Canada</b>							
AURINIA PHARMACEUT.	CA05156V1022	0	0	30,000	21.500	545,616.04	0.22
TRILLIUM THERAPEUTICS	CA89620X5064	0	0	80,000	17.360	1,174,808.61	0.47
Total issue country Canada						<u>1,720,424.65</u>	<u>0.69</u>
<b>Issue country Netherlands</b>							
ARGENS SE SP.ADR/1 -.10	US04016X1019	0	0	6,500	322.000	1,770,502.90	0.71
UNIQUIRE N.V. EO -.05	NL0010696654	0	0	49,000	36.390	1,508,361.88	0.60
Total issue country Netherlands						<u>3,278,864.78</u>	<u>1.31</u>
<b>Issue country Switzerland</b>							
CRISPR THERAPEUT. SF -.03	CH0334081137	0	0	15,700	116.300	1,544,567.10	0.62
Total issue country Switzerland						<u>1,544,567.10</u>	<u>0.62</u>
<b>Issue country Spain</b>							
GRIFOLS SP.ADR B EO-.10 1	US3984384087	0	0	42,156	14.340	511,370.84	0.20
Total issue country Spain						<u>511,370.84</u>	<u>0.20</u>
<b>Issue country USA</b>							
ACADIA PHARMACEUT. DL-.01	US0042251084	0	0	101,500	15.780	1,354,878.82	0.54
ACCELERON PHARMA DL -.001	US00434H1086	0	0	21,600	132.190	2,415,348.31	0.96
AD.BIOTECH.CORP. DL-.0001	US00650F1093	0	0	35,700	36.270	1,095,325.47	0.44
AGIOS PHARMACEUT. DL-.001	US00847X1046	0	15,700	40,200	45.680	1,553,386.63	0.62

Security designation	ISIN number	Purch./ additions Units/nominal (nom. in 1,000, rounded)	Sales/ disposals	Holding	Price	Value in EUR	% share of fund assets
ALNYLAM PHARMACE.DL-.0001	US02043Q1076	0	6,400	35,600	187.970	5,660,645.43	2.26
AMGEN INC. DL-.0001	US0311621009	3,000	16,300	93,900	216.040	17,160,390.81	6.85
AMICUS THERAPEUTICS INC.	US03152W1099	0	0	132,000	10.820	1,208,171.55	0.48
APELLIS PHARMACT.DL-.0001	US03753U1060	0	16,900	17,000	33.100	475,997.12	0.19
ARENA PHARMA.NEW DL-.0001	US0400476075	0	0	25,700	57.550	1,251,139.87	0.50
ARROWHEAD PHARMAC. DL-.01	US04280A1007	0	0	37,300	62.520	1,972,673.52	0.79
ATARA BIOTHERAP. DL-.0001	US0465131078	0	0	22,000	15.660	291,435.10	0.12
BIOGEN INC. DL -.0005	US09062X1037	16,350	2,150	57,400	295.950	14,370,029.18	5.74
BIOMARIN PHAR. DL-.001	US09061G1013	0	4,200	61,300	76.170	3,949,770.33	1.58
BLUEBIRD BIO INC. DL-.01	US09609G1004	0	0	15,000	17.560	222,814.36	0.09
BLUEPRINT MED.CORP.DL-001	US09627Y1091	0	0	27,600	100.030	2,335,429.51	0.93
BRIDGEBIO PHARMA DL-.001	US10806X1028	0	19,200	57,225	48.730	2,358,900.52	0.94
BRISTOL-MYERS SQUIBBDL-10	US1101221083	0	4,300	42,700	62.110	2,243,452.18	0.90
CHEMOCENTRYX INC.	US16383L1061	0	43,500	16,500	15.670	218,715.90	0.09
DECIPHERA PHARMAC. DL-.01	US24344T1016	0	0	18,300	31.790	492,117.75	0.20
DENALI THERAP.INC. DL-.01	US24823R1059	0	0	30,600	51.830	1,341,621.62	0.54
EDITAS MEDICINE DL-.0001	US28106W1036	0	0	19,000	60.790	977,041.83	0.39
EXACT SCIEN. DL-.01	US30063P1057	0	0	21,900	97.060	1,798,091.61	0.72
EXELIXIS INC. DL-.01	US30161Q1040	0	16,500	74,500	20.130	1,268,608.04	0.51
FATE THERAPEUTICS DL-.001	US31189P1021	0	0	17,200	64.810	942,970.01	0.38
GILEAD SCIENCES DL-.001	US3755581036	0	0	272,700	70.450	16,251,503.62	6.49
GLOBAL BL.THERAP. DL-.01	US37890U1088	0	0	53,500	26.290	1,189,794.02	0.47
GUARDANT HEALTH CL. A	US40131M1099	0	6,000	44,600	127.010	4,791,816.61	1.91
HALOZYME THERAPEU.DL-.001	US40637H1095	0	0	53,700	41.400	1,880,624.29	0.75
HOMOLOGY MED. DL-.0001	US4380831077	0	0	57,500	7.480	363,828.62	0.15
IGM BIOSCIENCES DL-.01	US4495851085	0	0	6,500	67.780	372,685.36	0.15
ILLUMINA INC. DL-.01	US4523271090	0	2,800	34,500	448.850	13,099,289.43	5.23
INCYTE DL-.001	US45337C1027	0	5,800	51,900	72.240	3,171,556.91	1.27
INSMED INC. DL-.01	US4576693075	0	0	47,600	27.300	1,099,251.36	0.44
INTELLIA THERAPEU DL-.01	US45826J1051	0	0	9,800	153.970	1,276,408.24	0.51
INTRA-CELLUL.THE.DL-.0001	US46116X1019	0	0	21,000	32.770	582,134.25	0.23
IONIS PHARMACEUT. DL-001	US4622221004	16,800	17,000	51,300	36.210	1,571,351.35	0.63
IOVANCE BIOTHERAP.DL-.001	US4622601007	0	0	64,000	21.740	1,176,974.16	0.47
JOUNCE THERAP. DL-.001	US4811161011	0	0	50,000	7.240	306,221.71	0.12
KALA PHARMACEUT. DL-.001	US4831191030	0	0	105,000	3.050	270,904.71	0.11
KODIAK SCIENCES DL-.0001	US50015M1099	0	0	13,700	93.910	1,088,328.05	0.43
KURA ONCOLOGY DL-.0001	US50127T1097	0	0	58,000	19.850	973,903.48	0.39
LIGAND PHARMAC.NEW DL-001	US53220K5048	0	0	4,300	132.040	480,287.61	0.19
MACROGENICS INC. DL-.01	US5560991094	0	0	18,000	27.200	414,160.64	0.17
MEDPACE HOLDINGS DL-.01	US58506Q1094	0	2,250	8,450	181.070	1,294,287.10	0.52
MIRATI THERAPEUTICS DL-01	US60468T1051	0	0	13,200	160.200	1,788,808.53	0.71
MODERNA INC. DL-.0001	US60770K1079	76,700	14,700	62,000	427.710	22,432,026.39	8.95
NANOSTR.TECHNOL. DL-.0001	US63009R1095	0	0	4,700	55.950	222,446.39	0.09
NEKTAR THERAPEUTICS	US6402681083	0	0	46,800	15.970	632,234.49	0.25
NEUROCRINE BIOSCI. DL-001	US64125C1099	0	0	24,900	94.620	1,993,011.04	0.80
NOVAVAX INC. DL-.01	US6700024010	0	11,900	17,600	234.290	3,488,139.41	1.39
OCULAR THERAPEUT.DL-.0001	US67576A1007	0	0	69,800	10.700	631,781.08	0.25
PAC.BIOSCI.OF CAL.DL-.001	US69404D1081	0	0	26,200	28.160	624,110.31	0.25
PACIRA BIOSCIENC. DL-.001	US6951271005	0	0	14,400	54.640	665,580.51	0.27

## ERSTE STOCK BIOTEC

Security designation	ISIN number	Purch./ additions Units/nominal (nom. in 1,000, rounded)	Sales/ disposals	Holding	Price	Value in EUR	% share of fund assets
PTC THERAPEUTICS DL-.001	US69366J2006	0	0	41,800	40.990	1,449,377.83	0.58
RADIUS HEALTH INC.DL-0001	US7504692077	0	0	15,000	12.390	157,213.55	0.06
REATA PHARMA INC. 0.001	US75615P1030	0	0	17,700	106.420	1,593,396.78	0.64
REGENERON PHARMAC.DL-.001	US75886F1075	0	9,450	21,070	645.150	11,498,803.45	4.59
REGENXBIO INC. DL-.0001	US75901B1070	0	0	13,000	45.680	502,338.96	0.20
REPLIMUNE GR. INC DL-.001	US76029N1063	0	0	11,900	31.280	314,877.13	0.13
REVOLUTION MED. DL-.0001	US76155X1000	0	0	17,400	29.550	434,944.80	0.17
ROCKET PHARMAT. DL-.01	US77313F1066	0	0	16,700	34.150	482,430.32	0.19
SAGE THERAPEUTICS DL-0001	US78667J1088	0	0	33,500	43.600	1,235,545.40	0.49
SANGAMO THERAP.INC.DL-.01	US8006771062	0	0	38,000	9.140	293,803.66	0.12
SAREPTA THERAP. DL-.0001	US8036071004	28,600	22,100	28,600	80.280	1,942,230.68	0.78
SCHOLAR ROCK HLDG DL-.001	US80706P1030	0	0	10,300	40.620	353,919.55	0.14
SEAGEN INC. DL-.001	US81181C1045	0	0	30,850	150.460	3,926,482.26	1.57
SERES THERAPEUT. DL -.001	US81750R1023	0	0	27,000	5.460	124,704.99	0.05
STOKE THERAPEUT.DL-.001	US86150R1077	0	0	9,200	23.930	186,233.56	0.07
SYNEOS HEALTH A DL-.01	US87166B1026	0	3,300	24,700	95.120	1,987,449.99	0.79
TRAVERE THERAP. DL -.0001	US89422G1076	0	0	35,600	23.610	711,006.22	0.28
TWIST BIOSCIENCEDL-.00001	US90184D1000	0	6,900	5,000	114.080	482,510.68	0.19
ULTRAGENYX PHARM. DL-.001	US90400D1081	0	0	17,210	95.150	1,385,214.65	0.55
UTD THERAP. (DEL.) DL-.01	US91307C1027	10,500	0	10,500	208.470	1,851,655.88	0.74
VAXCYTE INC. DL -.001	US92243G1085	0	0	14,200	25.920	311,351.35	0.12
VERACYTE INC. DL-.001	US92337F1075	0	0	17,000	46.910	674,592.90	0.27
VERTEX PHARMAC. DL-.01	US92532F1003	0	7,300	61,100	188.410	9,738,062.85	3.89
VOYAGER THERAP. DL -.001	US92915B1061	0	0	138,900	3.250	381,867.78	0.15
XENCOR INC. DL-.01	US98401F1057	0	0	32,200	32.730	891,516.31	0.36
ZOGENIX INC. DL-.001	US98978L2043	0	0	154,900	14.620	1,915,694.29	0.76
Total issue country USA						<u>195,919,630.96</u>	<u>78.19</u>

### Issue country British Virgin Islands

BIOHAVEN PHARMAC.HLDG CO.	VGG111961055	24,600	0	24,600	135.340	2,816,363.41	1.12
Total issue country British Virgin Islands						<u>2,816,363.41</u>	<u>1.12</u>
Total equities denominated in USD translated at a rate of 1.18215						<u>232,951,319.08</u>	<u>92.97</u>
Total securities admitted to organised markets						<u>232,951,319.08</u>	<u>92.97</u>

### Unlisted securities

#### Equities denominated in USD

#### Issue country USA

ADURO BIOT. - US007CVR0124	QOXDBM073949	0	0	21,400	0.000	0.00	0.00
Total issue country USA						<u>0.00</u>	<u>0.00</u>
Total equities denominated in USD translated at a rate of 1.18215						<u>0.00</u>	<u>0.00</u>
Total unlisted securities						<u>0.00</u>	<u>0.00</u>



**Breakdown of fund assets**

Transferable securities	245,122,235.38	97.83
Bank balances	5,511,249.71	2.20
Dividend entitlements	130,286.62	0.05
Other deferred items	-206,178.97	-0.08
<b>Fund assets</b>	<b>250,557,592.74</b>	<b>100.00</b>

**Investor note:**

**The values of assets in illiquid markets may deviate from their actual selling prices.**

Dividend-bearing units outstanding	AT0000746748	units	80,720.060
Value of dividend-bearing unit	AT0000746748	EUR	491.64
Dividend-bearing units outstanding	AT0000A1YFC3	units	0.000
Value of dividend-bearing unit	AT0000A1YFC3	EUR	122.44
Dividend-bearing units outstanding	AT0000A25NL2	units	0.000
Value of dividend-bearing unit	AT0000A25NL2	EUR	108.66
Non-dividend-bearing units outstanding	AT0000746755	units	279,513.396
Value of non-dividend-bearing unit	AT0000746755	EUR	491.62
Non-dividend-bearing units outstanding	AT0000A1YFD1	units	0.000
Value of non-dividend-bearing unit	AT0000A1YFD1	EUR	121.48
KEST-exempt non-dividend-bearing units outstanding	AT0000673165	units	18,029.866
Value of KEST-exempt non-dividend-bearing unit	AT0000673165	EUR	537.86
KEST-exempt non-dividend-bearing units outstanding	AT0000A0XYP0	units	98,540.129
Value of KEST-exempt non-dividend-bearing unit	AT0000A0XYP0	CZK	13,641.27
KEST-exempt non-dividend-bearing units outstanding	AT0000A18XC5	units	19,970.395
Value of KEST-exempt non-dividend-bearing unit	AT0000A18XC5	HUF	188,102.82
KEST-exempt non-dividend-bearing units outstanding	AT0000A1YFE9	units	0.000
Value of KEST-exempt non-dividend-bearing unit	AT0000A1YFE9	EUR	124.76
KEST-exempt non-dividend-bearing units outstanding	AT0000A1YFG4	units	0.000
Value of KEST-exempt non-dividend-bearing unit	AT0000A1YFG4	CZK	3,114.73
KEST-exempt non-dividend-bearing units outstanding	AT0000A1YFF6	units	0.000
Value of KEST-exempt non-dividend-bearing unit	AT0000A1YFF6	HUF	43,876.32
KEST-exempt non-dividend-bearing units outstanding	AT0000A26HX7	units	0.000
Value of KEST-exempt non-dividend-bearing unit	AT0000A26HX7	EUR	104.43

---

## ERSTE STOCK BIOTEC

---

The fund is not permitted to engage in repurchase agreements pursuant to Regulation (EU) No. 2015/2365 (Regulation on Transparency of Securities Financing Transactions and of Reuse). For this reason, repurchase agreements were not employed.

No total return swaps pursuant to Regulation (EU) 2015/2365 (Regulation on Transparency of Securities Financing Transactions and of Reuse) were concluded for the fund during the reporting period.

The fund is not permitted to engage in securities lending agreements pursuant to Regulation (EU) No. 2015/2365 (Regulation on Transparency of Securities Financing Transactions and of Reuse). For this reason, securities lending agreements were not employed.

### **Explanation on disclosure pursuant to Delegated Regulation (EU) No. 2016/2251 supplementing Regulation (EU) No. 648/2012 of the European Parliament and of the Council on OTC derivatives, central counterparties, and trade repositories with regard to regulatory technical standards for risk-mitigation techniques for OTC derivative contracts not cleared by a central counterparty:**

All OTC derivatives are traded through Erste Group Bank AG.

In the event of negative derivatives exposure, collateral in the form of cash or bonds is pledged to Erste Group Bank AG in accordance with the contractually agreed threshold.

In the event of positive derivatives exposure, EUR-denominated government bonds from the Republic of Austria and/or the Federal Republic of Germany are pledged by Erste Group Bank AG to the fund in accordance with the contractually agreed threshold. A one-time discount of 4% is agreed with the counterparty for this collateral. Collateral that would require a higher discount pursuant to Annex II to Delegated Regulation (EU) No. 2016/2251 is not accepted.

### **Purchases and sales of transferable securities in the reporting period not listed in the statement of assets and liabilities**

<b>Security designation</b>	<b>ISIN number</b>	<b>Purch./ additions</b>	<b>Sales/ disposals</b>
<b>Units/nominal (nom. in 1,000, rounded)</b>			
<b>Publicly traded securities</b>			
<b>Equities denominated in USD</b>			
<b>Issue country Cayman Islands</b>			
CHINA BIOL.PRODS HLDGS	KYG215151047	0	10,100
<b>Issue country USA</b>			
CONSTELL. PHARMACEUTICALS	US2103731061	0	12,300

<b>Security designation</b>	<b>ISIN number</b>	<b>Purch./ additions Units/nominal (nom. in 1,000, rounded)</b>	<b>Sales/ disposals</b>
-----------------------------	------------------------	---	-----------------------------

**Securities admitted to organised markets****Equities denominated in USD****Issue country Ireland**

ICON PLC EO-.06	IE0005711209	6,971	6,971
-----------------	--------------	-------	-------

**Issue country USA**

ALEXION PHARMAC. DL-.0001	US0153511094	0	57,650
AXSOME THERAPEUT. DL-0001	US05464T1043	0	11,500
FIBROGEN INC. DL-.01	US31572Q8087	0	93,300
PRA HEALTH SCIENC.DL -.01	US69354M1080	0	16,900

Vienna, September 2021

Erste Asset Management GmbH  
Electronically signed

Inspection information: The electronic signatures of this document can be inspected at the website of Rundfunk und Regulierungs-GmbH (<https://www.signatur.rtr.at/de/vd/Pruefung.html>).

Note: This document was signed with two qualified electronic signatures. A qualified electronic signature has the same legal effect as a hand-written signature (Art 25 of Regulation [EU] No 910/2014 [eIDAS Regulation]).